Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It se… Read more
Neuraxis, Inc. (NRXS) - Total Assets
Latest total assets as of September 2025: $5.78 Million USD
Based on the latest financial reports, Neuraxis, Inc. (NRXS) holds total assets worth $5.78 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neuraxis, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Neuraxis, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neuraxis, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Neuraxis, Inc.'s total assets of $5.78 Million consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.7% |
| Accounts Receivable | $244.62K | 5.1% |
| Inventory | $44.33K | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $96.59K | 2.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Neuraxis, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuraxis, Inc.'s current assets represent 89.7% of total assets in 2024, an increase from 88.3% in 2020.
- Cash Position: Cash and equivalents constituted 77.7% of total assets in 2024, up from 68.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 5.1% of total assets.
Neuraxis, Inc. Competitors by Total Assets
Key competitors of Neuraxis, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Neuraxis, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Neuraxis, Inc. generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neuraxis, Inc. is currently not profitable relative to its asset base.
Neuraxis, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 0.24 | 0.34 |
| Quick Ratio | 1.55 | 0.23 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.84 Million | $ -2.03 Million | $ -933.85K |
Neuraxis, Inc. - Advanced Valuation Insights
This section examines the relationship between Neuraxis, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.93 |
| Latest Market Cap to Assets Ratio | 4.93 |
| Asset Growth Rate (YoY) | 833.8% |
| Total Assets | $4.76 Million |
| Market Capitalization | $23.47 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuraxis, Inc.'s assets at a significant premium ( 4.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neuraxis, Inc.'s assets grew by 833.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuraxis, Inc. (2020–2024)
The table below shows the annual total assets of Neuraxis, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.76 Million | +833.78% |
| 2023-12-31 | $509.50K | -65.59% |
| 2022-12-31 | $1.48 Million | +94.70% |
| 2021-12-31 | $760.48K | -72.74% |
| 2020-12-31 | $2.79 Million | -- |